180 related articles for article (PubMed ID: 11737519)
1. CD34 expression in desmoplastic melanoma.
Hoang MP; Selim MA; Bentley RC; Burchette JL; Shea CR
J Cutan Pathol; 2001 Nov; 28(10):508-12. PubMed ID: 11737519
[TBL] [Abstract][Full Text] [Related]
2. Tyrosinase expression in malignant melanoma, desmoplastic melanoma, and peripheral nerve tumors.
Boyle JL; Haupt HM; Stern JB; Multhaupt HA
Arch Pathol Lab Med; 2002 Jul; 126(7):816-22. PubMed ID: 12088451
[TBL] [Abstract][Full Text] [Related]
3. Atrophic and plaquelike dermatofibrosarcoma protuberans.
Davis DA; Sánchez RL
Am J Dermatopathol; 1998 Oct; 20(5):498-501. PubMed ID: 9790114
[TBL] [Abstract][Full Text] [Related]
4. Palisading and verocay body-prominent dermatofibrosarcoma protuberans: a report of three cases.
Llatjós R; Fernández-Figueras MT; Díaz-Cascajo C; Ribera M; Ariza A
Histopathology; 2000 Nov; 37(5):452-5. PubMed ID: 11119127
[TBL] [Abstract][Full Text] [Related]
5. Neurofibromatous changes in dermatofibrosarcoma protuberans: a potential pitfall in the diagnosis of a serious cutaneous soft tissue neoplasm.
Kovarik CL; Hsu MY; Cockerell CJ
J Cutan Pathol; 2004 Aug; 31(7):492-6. PubMed ID: 15239679
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical characterization of dermatofibrosarcoma protuberans with practical applications for diagnosis and treatment.
Haycox CL; Odland PB; Olbricht SM; Piepkorn M
J Am Acad Dermatol; 1997 Sep; 37(3 Pt 1):438-44. PubMed ID: 9308560
[TBL] [Abstract][Full Text] [Related]
7. Dermatofibrosarcoma protuberans of the vulva: a mesenchymal tumour with a broad differential diagnosis and review of literature.
Gilani S; Al-Khafaji B
Pathologica; 2014 Dec; 106(4):338-41. PubMed ID: 25845051
[TBL] [Abstract][Full Text] [Related]
8. Dermatofibrosarcoma protuberans treated with Mohs surgery. A case with CD34 immunostaining variability.
Garcia C; Viehman G; Hitchcock M; Clark RE
Dermatol Surg; 1996 Feb; 22(2):177-9. PubMed ID: 8608381
[TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein D in CD34-positive and CD34-negative cutaneous neoplasms: a useful marker in differentiating superficial acral fibromyxoma from dermatofibrosarcoma protuberans.
Lisovsky M; Hoang MP; Dresser KA; Kapur P; Bhawan J; Mahalingam M
Mod Pathol; 2008 Jan; 21(1):31-8. PubMed ID: 17885669
[TBL] [Abstract][Full Text] [Related]
10. Dermatofibrosarcoma Protuberans of Distal Extremities and Acral Sites: A Clinicopathologic Analysis of 27 Cases.
Shah KK; McHugh JB; Folpe AL; Patel RM
Am J Surg Pathol; 2018 Mar; 42(3):413-419. PubMed ID: 29240584
[TBL] [Abstract][Full Text] [Related]
11. The Role of CD34 and D2-40 in the Differentiation of Dermatofibroma and Dermatofibrosarcoma Protuberans.
Sadullahoğlu C; Dere Y; Atasever TR; Öztop MT; Karaaslan Ö
Turk Patoloji Derg; 2017; 1(1):223-227. PubMed ID: 28832078
[TBL] [Abstract][Full Text] [Related]
12. Atrophic dermatofibrosarcoma protuberans: a case report and reappraisal of the literature.
Sheehan DJ; Madkan V; Strickling WA; Peterson CM
Cutis; 2004 Oct; 74(4):237-42. PubMed ID: 15551716
[TBL] [Abstract][Full Text] [Related]
13. Differential expression of HMGA1 and HMGA2 in dermatofibroma and dermatofibrosarcoma protuberans: potential diagnostic applications, and comparison with histologic findings, CD34, and factor XIIIa immunoreactivity.
Li N; McNiff J; Hui P; Manfioletti G; Tallini G
Am J Dermatopathol; 2004 Aug; 26(4):267-72. PubMed ID: 15249855
[TBL] [Abstract][Full Text] [Related]
14. Indeterminate fibrohistiocytic lesions of the skin: is there a spectrum between dermatofibroma and dermatofibrosarcoma protuberans?
Horenstein MG; Prieto VG; Nuckols JD; Burchette JL; Shea CR
Am J Surg Pathol; 2000 Jul; 24(7):996-1003. PubMed ID: 10895822
[TBL] [Abstract][Full Text] [Related]
15. Primary dermatofibrosarcoma protuberans of orbit--a rare entity.
Rahman T; Bhattacharjee K; Sarma JD; Dey D; Kuri G
Orbit; 2013 Apr; 32(2):127-9. PubMed ID: 23448305
[TBL] [Abstract][Full Text] [Related]
16. Fibrosarcomatous ("high-grade") dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance.
Mentzel T; Beham A; Katenkamp D; Dei Tos AP; Fletcher CD
Am J Surg Pathol; 1998 May; 22(5):576-87. PubMed ID: 9591728
[TBL] [Abstract][Full Text] [Related]
17. Fibrosarcomatous dermatofibrosarcoma protuberans with giant rosettes.
Zamecnik M
Am J Dermatopathol; 2001 Feb; 23(1):41-5. PubMed ID: 11176051
[TBL] [Abstract][Full Text] [Related]
18. Tenascin differentiates dermatofibroma from dermatofibrosarcoma protuberans: comparison with CD34 and factor XIIIa.
Kahn HJ; Fekete E; From L
Hum Pathol; 2001 Jan; 32(1):50-6. PubMed ID: 11172295
[TBL] [Abstract][Full Text] [Related]
19. Myxoid dermatofibrosarcoma protuberans: clinicopathologic, immunohistochemical, and molecular analysis of eight cases.
Mentzel T; Schärer L; Kazakov DV; Michal M
Am J Dermatopathol; 2007 Oct; 29(5):443-8. PubMed ID: 17890911
[TBL] [Abstract][Full Text] [Related]
20. Myxoid dermatofibrosarcoma protuberans: a rare variant analyzed in a series of 23 cases.
Reimann JD; Fletcher CD
Am J Surg Pathol; 2007 Sep; 31(9):1371-7. PubMed ID: 17721193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
